We have examined the possible role of metallothionein I/II (MT I/II) in Alzheimer's disease (AD), with a focus on the cellular localization of MT I/II relative to the astrocyte marker, glial fibrillary acidic protein (GFAP). In AD and preclinical AD cases, MT I/II immunolabeling was present in glial cells and did not show a spatial relationship with ␤-amyloid plaques or neurofibrillary pathology. There was a six-to sevenfold increase in both MT I/II-and GFAP-labeled cells in the gray matter of AD cases, relative to non-AD cases. However, there was a threefold increase in MT I/II-immunoreactive cells, but not GFAP-labeled cells, in the gray matter of preclinical AD cases compared to non-AD cases. Therefore, the specific increase in MT I/II is associated with the initial stages of the disease process, perhaps due to oxidative stress or the mismetabolism of heavy metals.
INTRODUCTION
Metallothioneins (MT) are cysteine-rich (23-33 mol%) proteins of low molecular weight (6-7 kDa). The MT family now consists of at least four different isoforms which are found throughout a variety of tissues (Erickson et al., 1997; Nakajima and Suzuki, 1995; Zheng et al., 1995) . Isoforms I and II are found in most tissues, isoform III in the brain and isoform IV in stratified squamous epithelia (Erickson et al., 1997) . MTs have been shown to be induced, or regulated, by a number of different factors including bacterial endotoxins, oxidative stress, heavy metals, and various cytokines and polypeptide hormones (Anezaki et al., 1995; Dalton et al., 1995; Ebadi et al., 1995; Zheng et al., 1995) . Within the body, MTs may have a role in sequestering heavy metals such as Zn(II) and Cu(I) (7-12 ions/MT), regulating the availability of metals to various enzymes and transcription factors. In this fashion, MTs may influence a host of biological processes such as DNA transcription, protein synthesis, and replication. MTs could also contribute toward the detoxification of heavy metals and act as an intracellular antioxidant.
Alzheimer's disease (AD) is a progressive neurodegenerative disease and is the major cause of dementia in people over 65 years of age. With respect to AD, much emphasis has been placed on the potential role of MT III in the progression of the disease. MT III possesses a unique growth inhibitory function which has been shown to suppress neuronal growth (Masters et al., 1994; Palmiter et al., 1992; Vallee, 1995) . MT III, reported to be downregulated in AD (Tsuji et al., 1992; Uchida & Ihara, 1995; Uchida et al., 1991) , may, therefore, potentiate the aberrant neuronal sprouting associated with this disease (Vickers, 1997) . Of interest in this study, however, was the possible role that MT I/II may play in AD. These isoforms, which are expressed in similar concentrations and similar locations within the brain as MT III (Aschner et al., 1997; Nakajima & Suzuki, 1995) , have not been extensively investigated in relation to AD. Existing reports show that MT I/II mRNA is upregulated in the AD brain (Duguid et al., 1989; Nakajima & Suzuki, 1995) . This increase was correlated with an increase in GFAP mRNA, and so it was postulated that elevated MT I/II expression may
